Gilead Sciences announces acquisition of Arcellx for $7.8B, gaining full control of promising CAR T-cell therapy anito-cel for multiple myeloma patients, with deal expected to close in Q2 2026.
Wells Fargo initiates coverage of Arcellx with an Overweight rating and a $100 price target, citing strong potential for its CAR-T therapy anito-cel in multiple myeloma.
New data confirms Arcellx’s anito-cel is a powerful and safe CAR-T cell therapy for relapsed or refractory multiple myeloma, showing deep, durable responses.
Guggenheim analyst says Arcellx stock decline is overdone after competitor Kelonia released early Phase 1 CAR-T therapy data. Maintains Buy rating despite market pressure.
